Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

RVMD - Revolution Medicines, Inc. So'nggi... | Finranks

Home

/

RVMD

R

Revolution Medicines, Inc. (RVMD)

NMS – Real vaqt narxi. Valyuta: USD

205.26

-0.29 (-0.14%)

Yopilishda: Aug 12, 2026, 3:59 PM EDT

205.26

0.00 (0.00%)

Bozor oldidan: Aug 13, 2026, 4:00 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Why Revolution Medicines May Be Big Pharma's Next Takeover Target

Why Revolution Medicines May Be Big Pharma's Next Takeover Target

Revolution Medicines (NASDAQ:RVMD | RVMD Price Prediction) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform a market cap of $44.1 billion.

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution.

High Risk, High Reward: Inside The Revolution Medicines Bull Case

High Risk, High Reward: Inside The Revolution Medicines Bull Case

Revolution Medicines is evolving from a clinical-stage biotech to a near-term commercial oncology player, anchored by its RAS(ON) inhibitor platform. RVMD's robust $3.9 billion cash position and additional committed capital support aggressive pipeline expansion and commercial launch readiness, reducing near-term dilution risk. Daraxonrasib's potential FDA approval and commercial launch in pancreatic cancer could fundamentally transform RVMD's financial profile and validate its broader RAS-targeted strategy.

RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View

RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View

Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook again as investors weigh higher spending and pipeline progress.

Revolution Medicines Q2 Earnings Call Highlights

Revolution Medicines Q2 Earnings Call Highlights

Revolution Medicines NASDAQ: RVMD said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it advances daraxonrasib and other RAS-targeted therapies across pancreatic and lung cancer.

Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

Videolar

No Data

There is no data to display

Press-relizlar

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution.